Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
12 Results for "
TP53-mutant
" in MedChemExpress (MCE) Product Catalog:
Products (12)
12 Results for "TP53-mutant" in MCE Product Catalog:
52
52 Publications Verification
Synonyms: RG7388
Research Areas:
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
15
Target:
Research Areas:
Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance .
2
Target:
Research Areas:
PRIMA-1 (NSC-281668) is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
1
1 Cited Publications
Cat. No.: HY-P72257
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TP53; mutant Tumor Protein 53; Tumor Protein P53; Li-Fraumeni Syndrome; P53; Tumor Supressor P53; Cellular Tumor Antigen P53; Tumor Protein 53; LFS1; P53-Ex10 Isoform; Tumor Suppressor P53; Truncated TP53; Phosphoprotein P53; Truncated P53; Antigen NY-CO-
Species:
Human
Source:
E. coli
Cat. No.: HY-148837
CAS No.: 2883535-99-5
Target:
PROTACs c-Myc CD276/B7-H3 IAP Casein Kinase Eukaryotic Release Factor (eRF) Oxidative Phosphorylation Apoptosis
Research Areas:
GT19630 is an orally active c-Myc PROTAC targeted degrader based on the cereblon E3 ubiquitin ligase, with an IC50 of 1.5 nM against human c-Myc. GT19630 mediates the degradation of MYC, GSPT1, GSPT2, CK1 alpha, N-Myc, B7-H3 and XIAP, and disrupts the MYC-GSPT1 synergistic regulatory feedback loop. GT19630 inhibits cell proliferation, blocks S-phase progression of the cell cycle, promotes cell apoptosis, reduces cell migration capacity, induces integrated stress response, and blocks oxidative phosphorylation by inhibiting the TCA cycle. GT19630 can be used in the research of Myc-driven hematological cancers, small cell lung cancer, breast cancer, TP53-mutant cancers, and venetoclax-resistant cancers .
Cat. No.: HY-P11089
CAS No.: 151808-74-1
Cat. No.: HY-153939S
Purity: 99.57%
Synonyms: RG7388-d3-1
Cat. No.: HY-15676R
CAS No.: 1229705-06-9
Synonyms: RG7388 (Standard)
Idasanutlin (Standard) (RG7388 (Standard)) is the analytical standard of Idasanutlin (HY-15676). This product is intended for research and analytical applications. Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
Cat. No.: HY-P71703
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TP53; mutant Tumor Protein 53; Tumor Protein P53; Li-Fraumeni Syndrome; P53; Tumor Supressor P53; Cellular Tumor Antigen P53; Tumor Protein 53; LFS1; P53-Ex10 Isoform; Tumor Suppressor P53; Truncated TP53; Phosphoprotein P53; Truncated P53; Antigen NY-CO-
Species:
Rat
Source:
E. coli
Cat. No.: HY-P74657
Purity: ≥ 80%, as determined by reducing SDS-PAGE.
Synonyms: TP53; mutant Tumor Protein 53; Tumor Protein P53; Li-Fraumeni Syndrome; P53; Tumor Supressor P53; Cellular Tumor Antigen P53; Tumor Protein 53; LFS1; P53-Ex10 Isoform; Tumor Suppressor P53; Truncated TP53; Phosphoprotein P53; Truncated P53; Antigen NY-CO-
Species:
Rhesus Macaque
Source:
E. coli
Cat. No.: HY-P705518
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: TP53; mutant Tumor Protein 53; Tumor Protein P53; Li-Fraumeni Syndrome; P53; Tumor Supressor P53; Cellular Tumor Antigen P53; Tumor Protein 53; LFS1; P53-Ex10 Isoform; Tumor Suppressor P53; Truncated TP53; Phosphoprotein P53; Truncated P53; Antigen NY-CO-
Species:
Human
Source:
E. coli
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
